Zobrazeno 1 - 10
of 125
pro vyhledávání: ''
Autor:
Michael Constantine, Romualdo Barroso-Sousa, Tianyu Li, Eric P. Winer, Meredith Faggen, Antonio Di Meglio, Nabihah Tayob, Harold J. Burstein, Caroline Block, Natalie Faye Sinclair, Rebecca Rees, Nan Lin, Ann H. Partridge, Ines Vaz-Luis, Sara M. Tolaney, Jiani Hu, Michael J. Hassett, Jose Pablo Leone, Lindsey Milisits, Frederick Briccetti, Lorenzo Trippa, Adrienne G. Waks
Publikováno v:
The Oncologist
Background In early trials, hypersensitivity reactions (HSRs) to paclitaxel were common, thus prompting the administration of antihistamines and corticosteroids before every paclitaxel dose. We tested the safety of omitting corticosteroids after cycl
Autor:
Joseph Kim, Dana Backlund Cardin, Yu Shyr, Patricia LoRusso, S. Percy Ivy, Shumei Kato, Ulka N. Vaishampayan, Peter M. Glazer, Steven R. Grossman
Publikováno v:
The Oncologist
Lessons Learned Background Cediranib, a vascular endothelial growth factor receptor inhibitor, suppresses expression of BRCA1/2 and RAD51 inducing homologous recombination DNA repair deficiency (HRD) in several cancer cell lines and xenograft models
Autor:
Jill Schwartz Gomez, Gary J. Whitman, Abigail S. Caudle, Joe Ensor, Kimberly B. Koenig, Juhee Song, Bora Lim, Mariana Chavez-MacGregor, Savitri Krishnamurthy, Vicente Valero, Simona F. Shaitelman, Nuhad K. Ibrahim
Publikováno v:
The Oncologist
Lessons Learned The combination of eribulin with 5-fluorouracil, either doxorubicin or epirubicin, and cyclophosphamide (FAC/FEC) was not superior to the combination of paclitaxel with FAC/FEC and was associated with greater hematologic toxicity. Eri
Publikováno v:
Oncologist
Background There is limited literature on patterns of everolimus use and subsequent hospitalizations and emergency room (ER) visits in real-world clinical practice. In this study, we describe patterns of everolimus use and hospitalizations and ER vis
Autor:
Veronika Seebacher, Stephan Polterauer, Hossein Taghizadeh, Christoph Grimm, Alexander Reinthaller, Leonhard Müllauer, Gerald W. Prager, Stefanie Aust, Heinz Kölbl, Robert M. Mader
Publikováno v:
The Oncologist
Introduction Advanced gynecologic cancers have a poor prognosis and constitute a major challenge for adequate treatment strategies. By analyzing and targeting molecular alterations, molecular guided treatments may be a viable option for the treatment
Autor:
Giada Rizzi, Lee S. Schwartzberg, Rebecca Clark-Snow, Ekaterine Arkania, Richard J. Gralla, Rudolph M. Navari, Matti Aapro, Daniel Voisin, Rita Wickham, Irena Radyukova, Kamal Patel, Eric Roeland
Publikováno v:
The Oncologist
Background NEPA, a combination antiemetic of a neurokinin‐1 (NK1) receptor antagonist (RA) (netupitant [oral]/fosnetupitant [intravenous; IV]) and 5‐HT3RA, palonosetron] offers 5‐day CINV prevention with a single dose. Fosnetupitant solution co
Autor:
Claire Edgerly, Sergey Gorelyshev, Amanda Hemmerich, Eric Allan Severson, Yakov Chudnovsky, David E. Kram, Rachel L. Erlich, Joshua McCorkle, Alexander Savateev, Nicholas Britt, Daniel Duncan, Yuri Trunin, Jeffrey S. Ross, Andge Valiakhmetova, Andrew Rankin, Richard S.P. Huang, Vincent A. Miller, Shakti H. Ramkissoon, Julia A. Elvin, Alexander Konovalov
Publikováno v:
The Oncologist
For pediatric patients with high‐grade gliomas, standard‐of‐care treatment includes surgery, chemotherapy, and radiation therapy; however, most patients ultimately succumb to their disease. With advances in genomic characterization of pediatric
Autor:
Toshinobu Hayashi, Mototsugu Shimokawa, Keisuke Aiba, Hitoshi Kawazoe, Kazuo Tamura, Toshiaki Saeki, Hirotoshi Iihara
Publikováno v:
The Oncologist
Background We previously reported the results of a prospective study of chemotherapy‐induced nausea and vomiting (CINV) in a cohort of patients who received carboplatin‐based chemotherapy and were selected from a nationwide registry of those sche
Autor:
Suzanne F. Jones, Howard A. Burris, Joseph Stilwill, Dianna Shipley, Cindy Jacobs, John D. Hainsworth, David R. Spigel, Brian Hemphill, Kent C. Shih, Patrick J. Ward, Ray D. Page, Tarek Mekhail, Michael McCleod, Robert C. Whorf, David M. Waterhouse
Publikováno v:
The Oncologist. 24:e1409-e1416
Background This randomized, double-blinded, phase II trial evaluated the efficacy of carboplatin and pemetrexed plus either apatorsen, an antisense oligonucleotide targeting heat shock protein (Hsp) 27 mRNA, or placebo in patients with previously unt
Autor:
Daniel J. George, Joel Picus, Olwen Hahn, Darren R. Feldman, Shaker R. Dakhil, Meghara K. Walsh, Susan Halabi, Colin Hessel, Michael J. Morris, Toni K. Choueiri, Christian Scheffold, M. Dror Michaelson, Eric J. Small, Milan Mangeshkar
Publikováno v:
The Oncologist
The phase II CABOSUN trial compared cabozantinib with sunitinib as initial treatment in patients with advanced renal cell carcinoma of intermediate or poor risk. This article presents subgroup analyses by baseline patient characteristics.
Caboza
Caboza